[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]
{{output}}
Treatment options for metastatic prostate cancer have evolved and diversified considerably in recent years. In the hormone-sensitive setting (mHSPC), the combination of androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) or abir... ...
